Related Experiment Video
Updated: Jan 2, 2026
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
9.1K
Prognostication with circulating tumor DNA: is it ready for prime time?
1Division of Oncology, Department of Medicine, Stanford University, Stanford, CA.
Hematology. American Society of Hematology. Education Program
|December 7, 2019
Summary
Detecting circulating tumor DNA (ctDNA) in lymphoma patients shows promise for diagnosis and monitoring. This blood test can identify subtypes, predict treatment response, and detect relapse early.
Area of Science:
- Oncology
- Molecular Diagnostics
- Hematology
Background:
- Circulating tumor DNA (ctDNA) detection in blood plasma offers novel approaches for lymphoma management.
- Potential applications include mutation profiling, treatment response assessment, and minimal residual disease monitoring.
Purpose of the Study:
- To review methodologies for ctDNA detection in aggressive B-cell lymphomas.
- To compare the advantages of digital PCR, immunoglobulin receptor sequencing, and NGS.
- To highlight clinical applications and implementation challenges of ctDNA assays.
Main Methods:
- Digital polymerase chain reaction (dPCR).
- Targeted sequencing of immunoglobulin receptors.
- Targeted next-generation sequencing (NGS).
Main Results:
- ctDNA analysis can identify molecular subtypes (e.g., cell-of-origin, double-hit lymphomas) from pretreatment plasma.
- Molecular response prediction after initial therapy is feasible.
- Early detection of disease relapse before clinical manifestation is possible.
Conclusions:
- ctDNA detection methods are advancing lymphoma diagnostics and management.
- Clinical implementation requires addressing current assay challenges.
- Future applications hold significant potential for personalized lymphoma care.
